HBV-Derived Polypeptide Adjuvant for Stable Vaccine Immune Enhancement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccine development faces challenges in maintaining a high protective immune response over time, and there is a need for effective immune adjuvants that can enhance immunity and address differences in vaccine efficacy between animal experiments and clinical trials, particularly for infectious diseases like AIDS and tuberculosis.
Innovation Solution
A hepatitis B virus-derived polypeptide with a specific amino acid sequence (SEQ ID NO: 2) is used as an immune adjuvant, which can be administered alone or in combination with other adjuvants, enhancing immunity and vaccine efficacy by increasing cytokine expression and activating T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immune adjuvants are used to enhance vaccine efficacy, then immune response is improved, but mechanisms of action are difficult to identify and vaccine efficacy differs between animal experiments and clinical trials
Solution Approach 1:
The patent introduces a hepatitis B virus-derived polypeptide as an intermediary adjuvant component that mediates immune enhancement through a defined mechanism. This polypeptide serves as a bridge between the vaccine antigen and the immune system, providing a controllable and identifiable mechanism of action that can be consistently evaluated across different experimental and clinical settings.
Solution Approach 2:
The patent modifies immune response parameters by introducing a specific polypeptide adjuvant that changes the immunogenicity characteristics of the vaccine. This allows for controlled adjustment of immune response magnitude and duration, enabling better prediction and consistency between preclinical and clinical vaccine efficacy outcomes.
2Reliability
If vaccine development focuses on antigen technology, then antigen effectiveness is improved, but immune adjuvant importance is overlooked for preventing infectious diseases
Solution Approach 1:
The hepatitis B virus-derived polypeptide adjuvant exhibits multi-functionality by effectively enhancing various types of vaccines (DNA and protein vaccines) through different administration routes (intramuscular, intraperitoneal, and subcutaneous). This universal applicability allows the same adjuvant formulation to be adapted across different vaccine platforms and delivery methods, improving preventive efficacy without limiting versatility.
Solution Approach 2:
The patent creates a composite vaccine formulation by combining the hepatitis B virus-derived polypeptide with other adjuvants or vaccine components. This composite approach integrates multiple functional elements that work synergistically to enhance immune responses, addressing the need for both targeted antigen effectiveness and flexible adjuvant application in preventive vaccine development.
3Reliability
If various immune adjuvants are used in combination, then synergistic effects may appear, but side effects and complexity of combination research increase
Solution Approach 1:
The patent merges the hepatitis B virus-derived polypeptide with existing immune adjuvants to create a combined adjuvant system. This merging approach allows for synergistic immune enhancement while maintaining a relatively simple and well-defined composition, reducing the complexity of combination research compared to mixing multiple unrelated adjuvants.
Solution Approach 2:
The patent develops a composite adjuvant formulation integrating the hepatitis B virus-derived polypeptide with other adjuvant components. This composite structure provides a systematic approach to combination therapy, where each component's function is understood and controlled, thereby reducing overall combination research complexity while maintaining synergistic effectiveness.
Data Source
AI summary
Provided is an immune adjuvant including a polypeptide consisting of an amino acid sequence of SEQ ID NO: 2. The polypeptide is a hepatitis B virus-derived polypeptide, is effective in enhancing immunity through co-administration with vaccines as a single immune adjuvant, and in particular, when co-administered with another immune adjuvant, may exhibit a more remarkable immunity enhancement effect. Furthermore, the polypeptide is a single molecule having only 6 amino acids, is not cytotoxic, and has excellent in vivo stability.